Introduction
smooth muscle cell accumulation [2] . This involves proliferation, chemotactic migration into the intimal layers of Despite significant improvements in the primary success the vessel, and secretion of extracellular matrix proteins rates of medical and surgical treatments of atherosclerotic [3, 4] . disease, secondary failure due to late restenosis continues b-Blockers play an important role in the treatment of to occur in 30-50% of individuals [1] . Restenosis after ischemic heart disease [5] [6] [7] [8] . According to their relative vascular injury probably results from the interdependent ability to antagonize the actions of sympathomimetic actions of the ensuing thrombosis, inflammation, liberation amines, b-adrenergic antagonists may be classified as b -1 of potent growth-regulatory molecules such as plateletselective (i.e. metoprolol, bisoprolol) or nonselective (i.e. derived growth factor, basic fibroblast growth factor, and propranolol) inhibitors [9] . Moreover, certain b-blockers have additional vasodilating properties, such as carvedilol which blocks a-adrenergic receptors [10] , or bucindolol which exerts direct vasodilating actions [10] . The new HaECs were cultured on collagen-coated petri dishes in b-blocker nebivolol is a highly selective [11] and lipoa special growth medium (EGM-2-2-MV Bullet kit, Biophilic b -adrenergic receptor antagonist with vasodilating Whitakker, Verviers, Belgium) and fed every third day 1 characteristics [12] [13] [14] . The drug is devoid of intrinsic [19] . Passage numbers from 5 to 8 were used for the sympathomimetic or membrane stabilizing activity [15, 16] .
experiments. Mycoplasma contamination was excluded by Novel therapeutic agents to treat cardiovascular disease DNA staining with 49,6-diamidino-2-phenylindole should possess some of the following properties: (1) dihydrochloride (DAPI, Roche Molecular Biochemicals). improvement of prognosis in patients, (2) modulation of thrombosis and inflammation, (3) reversal of endothelial cell dysfunction, and (4) inhibition of vascular smooth 2.3. Cellular assays of HaECs and HaCSMCs muscle cell proliferation and migration.
The main aim of this study was to examine whether the Cells were seeded into 96-well plates at a density of 27 new b-blocker nebivolol exerts growth-inhibitory effects 10 000 cells per well. Incubation with nebivolol (10 -
25
on human coronary smooth muscle and endothelial cells. A 10 mol / l) was started 24 h after cells were adherent. further objective was to compare the antiproliferative After 1, 2, 4, 7 and 14 days, final cell numbers were properties of nebivolol with other b-blockers. Furthermore, measured by incorporation of bromodeoxyuridine (BrdU) the effect of nebivolol on NO and endothelin-1 formation using a cell proliferation ELISA (Roche Molecular Bioin human coronary endothelial cells was analyzed. chemicals) [18] . MTT tests, which measure metabolic activity as an indirect marker for cell proliferation, were performed according to the manufacturer's instructions 2. Methods (Sigma) [18] .
Drugs 2.4. Measurement of apoptosis of HaECs and HaCSMCs
Propranolol and metoprolol were from Sigma (Deisenhofen, Germany). Bisoprolol was from Merck (Darmstadt, For determination of cell death haCSMC or HaECs were Germany) and carvedilol from Roche Molecular Biochemseeded into 6-well plates and treated with nebivolol 27 25 icals (Mannheim, Germany). Nebivolol (Berlin-Chemie, (10 -10 mol / l) for 24 h. The leakage of fragmented Berlin, Germany) is a lipophilic substance that was DNA from apoptotic nuclei was measured by the method dissolved in 100% methanol and diluted with three volof Nicoletti et al. [20] . Briefly, apoptotic nuclei were 23 umes of growth medium to obtain a stock solution of 10 prepared by lysing cells in hypotonic lysis buffer (1% mol / l. All further dilutions were prepared in growth sodium citrate, 0.1% Triton X-100, 50 mg / ml propidium medium and the final methanol concentration in the iodide) and analyzed by flow cytometry [18] . Nuclei to the experiments was 0.1%. Control cells received the diluent at left of the 2 N peak containing hypodiploid DNA were equal concentrations. considered as apoptotic [21] . Apoptosis was additionally detected by annexin V staining. Cells were grown on 2.2. Cell culture of HaECs and HaCSMCs coverslips and incubated with nebivolol for 24 h. Cells were rinsed PBS, pH 7.4, and incubated with FITC-labeled Human coronary arteries were obtained from two male annexin V (Roche Molecular Biochemicals). patients with end-stage cardiomyopathy (without macroscopic signs of atherosclerosis) undergoing heart transplantation (approved by the local ethics committee). The 2.5. Growth factors patients were on a medication with digitonin, furosemide, enalapril and warfarin. Human coronary smooth muscle For investigating the effects of growth factors haCSMC cells (haCSMCs) and human coronary endothelial cells were incubated with 20 ng / ml of either platelet-derived (haECs) from the left descending coronary artery were growth factor (PDGF)-AA, PDGF-BB or transforming passaged as described previously [17, 18] . The growth rate growth factor b (TGFb ), or 15 ng / ml basic fibroblast 1 1 of haCSMCs and haECs was identical in the two donors. growth factor (bFGF, each from R&D System, Wiesbaden, HaCSMCs were grown in a mixture of Waymouth MB Germany) in the presence of 10% FCS. Nebivolol was 752 / 1 medium and nutrient mixture F12 Ham (1:1, v / v) added 24 h after seeding of the cells. The concentrations supplemented with 10% FCS, 100 U / ml penicillin and 100 inducing maximal stimulatory effects on haCSMCs were mg / ml streptomycin (all from Gibco / BRL, Eggenstein, found in assays in which increasing concentrations (0.1, Germany). Smooth muscle origin was confirmed by im-10, 15, 20 and 40 ng / ml) of the growth factors were 27 munocytochemical stainings using monoclonal antibodies examined [18, 22] . The medium containing drug (10 -25 against smooth muscle a-actin (Progen, Heidelberg, Ger-10 mol / l) and growth factors was exchanged every third many).
day and haCSMC were incubated for 7 days.
Measurement of nitric oxide and endothelin-1 in 2.8. Statistical analysis haECs
Statistical analyses were performed using analysis of variance and Student's-Newman-Keuls test for the assessNitric oxide (NO) concentration was determined inment of significance. Results in which two or more directly by the diazotization method using a calorimetric treatment groups were compared were tested by means of kit (Roche Molecular Biochemicals) [23] . For the assay two-way ANOVA [18, 22] . P values ,0.05 were consid-40 000 haECs were seeded into 6-well plates and 24 h later ered to denote statistically significant differences. The data nebivolol was added. After 4 days of incubation growth are presented as the percentage of change compared to medium was collected, combined with an equal volume of control cultures. Each experiment was performed with six potassium phosphate, pH 7.5, and centrifuged at 2000 g for replicates. The mean6S.E.M. of these was used for 45 min through a nitrate-free ultrafilter. The ultrafiltrate statistical comparison of three to six different sets of (0.5 ml) was incubated for 10 min with NADPH (0.65 experiments. For each experiment cells of only one donor mg/ml), nitrate reductase (0.1 mU / ml), 1% sulfanilamide, were used. The IC is defined as the concentration that 0.1% N-(1-naphthyl)-ethylene diamine dihydrochloride. 50 resulted in an inhibition of 50% in cases where a maxiStabilized potassium nitrate was used as standard. The mum effect could be seen or deduced. detection limit was 0.2 mmol / l nitrate.
Endothelin-1 (ET-1) concentrations were measured after 4 days of incubation using a specific ELISA (Immundiagnostik, Bensheim, Germany). The ELISA had a crossreac-3. Results tion with ET-2, but did not detect ET-3 or Big-ET-1. The detection limit was 0.38 fmol / ml [24, 25] .
Effect of nebivolol on haCSMCs

Prepro ET-1 cDNA cloning and in situ haCSMCs were incubated with different concentrations hybridization of HaCECs
of nebivolol. Even after short incubation periods of 24, 48 h (Fig. 1A ) or 96 h (data not shown) the mitotic indices in the BrdU-ELISA were concentration-dependently reduced. Prepro ET-1 RNA probes for in situ hybridization were After 7 days of incubation, a significant reduction in cell synthesized from a 541-bp-cDNA fragment. The cDNA growth was apparent with an IC of 6.1 mmol / l (Fig. 1B) . 50 was obtained from A10 cells by reverse transcription PCR The MTT test showed comparable results. Incubation for using the sense primer GGAACAGATGCCAGTGTGCT up to 14 days did not result in any drug resistance (BrdU and the antisense primer CCAGACAGCAAGAAGAG-ELISA: IC 5.8 mmol / l, data not shown). Incubation for 7 50 GCA [26, 27] . The prepro ET-1 fragment (bp 503-1043) days in the presence of nebivolol followed by incubation was cloned into the multiple cloning site of pGEM-T without nebivolol for 7 additional days also showed a (Promega) flanked by Sp6 and T7 promoters. The insert concentration-dependent reduction in the growth rate was used as template for the generation of sense and (BrdU-ELISA: IC 5.7 mmol / l, MTT test: IC 6.0 mmol / 50 50 antisense RNA probes and labeled with digoxigenin-UTP l, Fig. 1C ). (Roche Molecular Biochemicals). In situ hybridization was performed as described by Ceol et al. [28] . Cells were fixed with 2% formaldehyde and washed in PBS. Prehy-3.2. Effect of nebivolol on growth factor-stimulated bridization buffer [50% formamide, 5% dextransulfate, 500
haCSMC proliferation mg / ml yeast t-RNA, 200 mg / ml herring sperm DNA, 10% DTT, 53SSC (0.3 mol / l NaCl and 0.3 mol / l sodium citrate) 13Denhardt's solution] was applied to the cells for In order to evaluate whether nebivolol could inhibit 3 h. The buffer was replaced by hybridization buffer (5 accelerated smooth muscle cell proliferation, haCSMCs mg / ml DIG-labeled RNA probe in prehybridization buffer)
were incubated with different growth factors, i.e. PDGFs, for 12 h at 468C. Slides were washed in 23SSC for 15 anti-DIG antibody (1:30) was applied to the slides in 0.5% nebivolol for 7 days (10 -10 mol / l) in the presence of BSA-PBST for 30 min. After washing in PBST a silver the growth factors inhibited proliferation dose-dependently 
Comparison of nebivolol with different b-blockers
Permanent incubation of haCSMCs with metoprolol, propranolol, bisoprolol, carvedilol or nebivolol (each 27 25 10 -10 mol / l) showed different growth-inhibitory effects. Continuous incubation with metoprolol or bisoprolol (data not shown) did not influence proliferation (Fig.  3A) or gross metabolic activity (Fig. 3B) . Propranolol even induced a discrete increase in cell proliferation (BrdU-ELISA 11864.0% vs. control of 10063.6%, n56, P, 0.01). Continuous incubation with carvedilol concentration-dependently reduced the proliferation (Fig. 3A) . In contrast, MTT staining actually increased in the presence of carvedilol, suggesting that metabolic activity increased in a concentration-dependent fashion up to 13063.6% at 25 10 mol / l (n56, P,0.01, Fig. 4B ). Nebivolol decreased both MTT staining and proliferation starting at a con- 
Effect of nebivolol on apoptosis in haCSMCs
L-NAME, an inhibitor of NO synthesis, did not inhibit the decrease in cell proliferation indicating that the antiproIn order to elucidate whether nebivolol induces apopliferative effect of nebivolol on haECs was not NO-depentosis, formation of hypodiploid DNA was measured. dent (data not shown). haCSMCs were incubated for 24 h with growth medium Incubation of haECs with different b-blockers showed before nebivolol was added for 48 h. Incorporation of comparable results as in haCSMCs: metoprolol and bisoppropidium iodide as a marker for membrane damage was rolol did not influence haEC proliferation or gross metaalso measured. Incubation with nebivolol concentrationbolic activity (data not shown). Propranolol again induced dependently induced apoptosis with an increase from 6% a discrete increase in metabolic activity (BrdU-ELISA
25
in control cells to 23% in cells treated with 10 mol / l 11665.0 vs. control of 10064.2%, n54, P,0.01). Incunebivolol (Fig. 4) . Equivalent data were obtained with bation with carvedilol reduced concentration-dependently (control) to 17% (nebivolol, data not shown). As a positive increase of apoptotic cells from 7 to 25% (data not shown) 25 control, the apoptotic agent staurosporine (10 mol / l) and a reduction of the haECs in the G -phase. 2 was added to the cells, resulting in 50% of cells undergoing apoptosis.
Effects of nebivolol on nitric oxide production in 3.6. Effect of nebivolol on proliferation and apoptosis in haECs haECs
In order to determine whether nebivolol increased NO Like in haCSMCs, nebivolol produced a concentrationproduction in vitro, haECs were incubated with increasing dependent decrease in the mitotic indices of haECs (IC concentrations of the drug for 4 days. NO was measured 50 6.8 mmol / l BrdU-ELISA, data not shown). The MTT test indirectly by analyzing the nitrate concentration in the revealed a statistically significant decrease in metabolic growth medium. As shown in Table 1 , an increase in 26 27 activity at 10 mol / l. Coincubation with 500 mmol / l nitrate formation was evident at 10 mol / l. Incubation with 500 mmol / l L-NAME inhibited nebivolol-induced of increasing concentrations of nebivolol, the ET-1 connitrate synthesis. centration in the growth medium decreased concentration-25 dependently to 0.1360.01 fmol / ml / 10 000 cells (10 3.8. Endothelin-1 secretion in haECs mol / l, 286%, P,0.001, n54). In the presence of 500 mmol / l L-NAME, nebivolol was not able to reduce ET-1 Since ET-1 has been implicated as an important medisecretion. Since ET-1 is not stored in vesicles but de novo ator in the pathogenesis of atherosclerosis, basal ET-1 synthesized, additionally in situ hybridization was persecretion into the growth medium was measured. In formed to determine prepro ET-1 mRNA synthesis in untreated cultures, haECs produced 0.560.05 fmol / ml / haECs. As shown in Fig. 5 , control cells produced high 10 000 cells ET-1 after 4 days ( Table 2 ). In the presence amounts of prepro ET-1 mRNA with a cytoplasmatic Concerning its effects on the cell cycle, nebivolol blocked the entry of cells into the G phase in haCSMCs 2 and haECs. Measurement of hypodiploid DNA, annexin V 4. Discussion and DAPI staining revealed that nebivolol dose-dependently induced apoptosis in maximally 25% of the cells The b-blockers nebivolol and carvedilol inhibit the without detectable signs of necrosis, whereas staurosporine proliferation of human coronary smooth muscle cells very induced apoptosis in more than 50% of the cells. This potently and concentration-dependently. An accelerated indicates that nebivolol induces only a moderately ingrowth rate induced by different growth factors was creased apoptotic rate in haCSMC and haECs. Such an significantly inhibited by nebivolol. Application of acceleration of apoptotic death processes may reduce nebivolol for 7 days followed by incubation for 7 additioncellular components in atherosclerotic lesions, such that al days without nebivolol did not reduce this growththe integrity and stability of the plaques are maintained inhibitory effect. Furthermore, haCSMCs did not develop [30, 31] . drug resistance after 14 days of continuous drug incubaSince NO is an endogenous anti-atherosclerotic moletion. Proliferation of haCSMC in vivo is inhibited by cule and because it was shown that nebivolol induced increased NO formation [29] . During nebivolol incubation relaxation of canine coronary arteries and human forearm haECs increased NO liberation and reduced prepro ET-1 arteries in vivo [12, 32] , we studied the effects of nebivolol 27 mRNA production with a subsequent decrease of ET-1 on haECs. Incubation of haECs with 10 mol / l nebivolol secretion. These effects of nebivolol may inhibit smooth increased NO formation at low concentrations. On the muscle cell proliferation either directly or indirectly other side, ET-1 secretion and prepro-ET-1 mRNA expresthrough an increased NO production of endothelial cells.
sion dose-dependently decreased in the cells. These actions on both haECs and haCSMCs make Such a spectrum of activities on haECs and haCSMCs nebivolol as a candidate drug for the prevention of has not been shown for any other classical b-blocker. restenosis or even the progression of atherosclerosis. One
Neither metoprolol, bisoprolol nor propranolol reduced caveat of this study is that the cells were isolated from proliferation, while only carvedilol reduced the growth rate of haCSMCs by 40% [33, 34] . Celiprolol even stimulated haECs in vitro were higher than those expected from cell growth of rat smooth muscle cells in vitro [33] . These pharmacokinetic studies in humans. However, serum levels data suggest that the antiproliferative properties of of b-blockers do not accurately reflect the local connebivolol are not the result of a b-adrenoceptor blockade.
centrations present in smooth muscle cells, because for Growth-inhibitory effects were seen with the voltage-deinstance propranolol has been demonstrated to accumulate pendent calcium channel blockers nifedipin and verapamil in myocardium [50] . In case of carvedilol growth-inhibusing high concentrations in vitro [35, 36] . Carvedilol, itory effects have been described at a dose of 10 mmol / l in however, exerts mild calcium channel-blocking properties vitro [33] . Although this represents a high concentration in at high concentrations [35, 36] . No evidence exists for an vitro, neointima formation was reduced after balloon action of nebivolol on voltage-dependent calcium chanangioplasty using a dose of only 1 mg / kg in vivo. This nels. Since nebivolol can inhibit the augmented proliferindicates that the in vivo levels and the in vitro conation of haCSMCs induced by various growth factors, the centrations needed to produce antimitogenic effects are site of growth inhibition occurs at some point beyond different. In addition to its growth inhibitory actions, growth factor receptor signaling at a distal common nebivolol reduced ET-1 secretion and increased NO propathway. Nebivolol also irreversibly inhibited haCSMC duction at concentrations that can be achieved in vivo. proliferation without overt cytotoxicity indicating that it Such additional mechanisms might further potentiate the might interact with cell cycle-regulatory proteins. In haECs anti-atherogenic effects of nebivolol in vivo by simulincubation with L-NAME did not inhibit the antiprolifertaneously acting on endothelial and smooth muscle cells. ative action of nebivolol indicating that NO is not responIn summary, nebivolol possesses several characteristics sible for growth inhibition.
of a modern pharmacological drug for treating carSince ET-1 can increase mitogenesis of growth factors diovascular disease. It (1) showed a potent growth-inhibby amplifying their effects on DNA synthesis [37, 38] , the itory effect in the absence but also in the presence of fact that nebivolol decreased ET-1 secretion is an imdifferent mitogens and (2) moderately induced apoptosis. portant point. Increased ET-1 secretion has been shown in Additionally, nebivolol may improve endothelial function the early phase of atherogenesis [39, 40] as well as in by increasing NO formation, thereby decreasing ET-1 unstable angina [25] . ET-1 promotes the production of secretion. extracellular matrix and the formation of fibroproliferative lesions [41, 42] , whereas blockade of endothelin receptors inhibited neointima formation after balloon angioplasty in
